SAHPRA is pleased to announce the appointment of a new Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, who will commence with this role in January 2020. Dr Semete-Makokotlela holds a Ph.D. in Biochemistry (North-West University) and an MSc in Management Finance and Investment from Wits Business...
Mr Khamusi Mutoti, Biological Medicine Manager at SAHPRA, was elected the Chairperson of the African Blood Regulator’s Forum (ABRF) during the African Medicines Regulation Conference (AMRC) held at Elephant Hill Hotel, Victoria Falls, Zimbabwe on 2 – 4 October 2019. Mr Mutoti who is also an...
The South African Health Products Regulatory Authority (SAHPRA) is updating certain active pharmaceutical ingredient (API) names used in South Africa to bring them into line with international nomenclature. Further name changes are also taking place – to improve consistency within South African approved terminology and...
10 May 2019 SAHPRA is the South African Health Products Regulatory Authority. It is a Section 3A public entity that was formed by the South African government to oversee the regulation of health products which includes medicines, medical devices, in-vitro diagnostic tests and devices, radiation emitting...
The Medicines Control Council wishes to inform prescribers of increased risks of cerebrovascular adverse events (including strokes and transient ischaemic attacks) and mortality associated with the use of atypical antipsychotics in elderly patients with dementia. The atypical antipsychotics to which this medicine safety alert refers...
